Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Jin Ho Choi MD

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2758-1370; OpenAlex author ID A5101924670, A5110168965. Sources: OpenAlex.

Their work

Papers
21 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
58
Papers, trials and grants by year

2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 4 papers · 2025: 3 papers · 2026: 4 papers

Papers 21

  1. Lorazepam and Survival in Asian Patients with Pancreatic Cancer: A Retrospective Cohort Study. First author DOI 10.1007/s12029-026-01429-7↗
  2. Characteristics of Pancreatic Cancer-associated Ascites and Redefined Criteria for Bacterial Peritonitis. Co-author DOI 10.1097/mpa.0000000000002606↗
  3. Treatment Outcomes in Frail Patients with Advanced Pancreatic Ductal Adenocarcinoma: A Real-World Comparison of Gemcitabine, S-1, and Stereotactic Ablative Rad… Co-author DOI 10.1159/000552276↗
  4. Ferroptosis-based therapeutic strategy targeting iron metabolism and SLC7A11 overcomes oxaliplatin resistance in patient-derived pancreatic cancer organoids. Co-author DOI 10.1186/s13046-026-03745-z↗
  5. Artificial Intelligence-Powered Spatial Analysis of Immune Phenotypes in Resected Pancreatic Cancer. First author DOI 10.1001/jamasurg.2025.1999↗
  6. Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer. Co-author DOI 10.1002/jcsm.13643↗
  7. Evaluation of Exosome-derived Small RNAs as Potential Biomarkers for Pancreatic Ductal Adenocarcinoma Using Next-generation Sequencing. Co-author DOI 10.3343/alm.2025.0121↗
  8. Establishment of a patient-specific avatar organoid model derived from EUS-guided fine-needle biopsy for timely clinical application in pancreatic ductal adeno… Co-author DOI 10.1016/j.gie.2024.02.021↗
  9. Prognostic value of the TP53 mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX. Co-author DOI 10.1177/17588359241290482↗
  10. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma an… Co-author DOI 10.1186/s12943-024-02003-0↗
  11. Antiproliferative Activity of Piceamycin by Regulating Alpha-Actinin-4 in Gemcitabine-Resistant Pancreatic Cancer Cells. First author DOI 10.4062/biomolther.2023.109↗
  12. Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Pancreatic Cancer Cells. Co-author DOI 10.3390/cancers15092642↗
  13. Cytokine-Induced Killer Cell Immunotherapy Combined With Gemcitabine Reduces Systemic Metastasis in Pancreatic Cancer: An Analysis Using Preclinical Adjuvant T… Co-author DOI 10.1097/mpa.0000000000002176↗
  14. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic a… Co-author DOI 10.1177/17588359221119539↗
  15. Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX. Co-author DOI 10.3389/fonc.2022.945829↗
  16. Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, p… Co-author DOI 10.1177/17588359211056179↗
  17. Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2020.05.005↗
  18. The association between use of statin or aspirin and pancreatic ductal adenocarcinoma: A nested case-control study in a Korean nationwide cohort. Co-author DOI 10.1002/cam4.2617↗
  19. Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment. Co-author DOI 10.1186/s12885-019-6193-0↗
  20. Comparison of Adjuvant Chemotherapy and Chemoradiation Therapy Efficacy for Pancreatic Cancer After R0 Resection: A Propensity Score-Matched Analysis Co-author DOI 10.21203/rs.2.12295/v1↗
  21. Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.5009/gnl18220↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ji Kon Ryu · 15 shared papers, 2018–2026 · strength 2.62
  2. Woo Hyun Paik · 14 shared papers, 2018–2026 · strength 2.47
  3. Sang Hyub Lee · 14 shared papers, 2018–2026 · strength 2.44
  4. In Rae Cho · 9 shared papers, 2022–2026 · strength 2.02
  5. Yong‐Tae Kim · 11 shared papers, 2018–2024 · strength 1.43
  6. Kyu Taek Lee · 5 shared papers, 2024–2025 · strength 0.95
  7. Joo Kyung Park · 5 shared papers, 2024–2025 · strength 0.95
  8. Tae Seung Lee · 2 shared papers, 2026 · strength 0.62
  9. Ja‐Lok Ku · 3 shared papers, 2023–2026 · strength 0.62
  10. Semin Lee · 3 shared papers, 2024–2025 · strength 0.57
  11. Jong Kyun Lee · 3 shared papers, 2024–2025 · strength 0.55
  12. Kee‐Taek Jang · 3 shared papers, 2024–2025 · strength 0.53
  13. Hye Min Kim · 3 shared papers, 2024–2025 · strength 0.53
  14. Hongbeom Kim · 3 shared papers, 2022–2025 · strength 0.52
  15. Young Hoon Choi · 2 shared papers, 2025 · strength 0.40
  16. Jong Kyun Lee · 2 shared papers, 2024–2025 · strength 0.40
  17. Min Su You · 4 shared papers, 2018–2019 · strength 0.39
  18. Jin Seok Heo · 2 shared papers, 2025 · strength 0.38
  19. In Woong Han · 2 shared papers, 2025 · strength 0.38
  20. Sang Hyun Shin · 2 shared papers, 2025 · strength 0.38
  21. J.H. Lee · 2 shared papers, 2023–2024 · strength 0.34
  22. Sang Kook Lee · 2 shared papers, 2023–2024 · strength 0.34
  23. Min Woo Lee · 2 shared papers, 2023–2024 · strength 0.34
  24. Gunn Huh · 3 shared papers, 2018–2021 · strength 0.33
  25. Chang Hyun Kim · 1 shared paper, 2026 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.